Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life
NCT07449351Phase 1Not yet recruiting
- Sponsor
- Yale University
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin (2 arms), sponsored by Yale University. Primary endpoints: Complex Working Memory Span Task - fMRI measure at 8 weeks, NEO-Five-Factor-Inventory at 8 weeks and 11 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT07449351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449351.